Novel Coronavirus Information Center

Elsevier’s free health and medical research on the novel coronavirus (SARS-CoV-2) and COVID-19

January 27, 2020 - Updated August 6, 2020
3D illustration of Coronavirus (© istock.com/Dr_Microbe)
3D illustration of Coronavirus (© istock.com/Dr_Microbe)

Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on SARS-CoV-2 (the novel coronavirus) and COVID-19 (the disease).

All resources are free to access and include guidelines for clinicians and patients.

See our directory of all Elsevier's COVID-19 resources

For researchers

Under the Research tab, you will find the latest early-stage and peer-reviewed research on COVID-19 from journals including The Lancet and Cell Press. We have also made more than 37,000 related articles and book chapters free to access on ScienceDirect.

View the 37,000+ free articles

These articles are also available to download with rights for full text and data mining, re-use and analyses for as long as needed. Username: public | Password: beat_corona (note: FTP client software/plugin needed to access download)

Download full text for data mining

We are also giving free access to Elsevier's clinical, biomedical and life sciences research resources and solutions to researchers focused on coronavirus drugs and vaccines or clinical research.

Gain free access to Elsevier biomedical tools

For clinicians

Under the Clinical information tab, you will find evidence-based skill guides and care plans for treatment, safety and patient education, along with emergency prepared webinars by the CDC.

For patients

In the Patient resources section, you can find our 3D4Medical coronavirus video, resources from the CDC and WHO, and information about Elsevier's Patient Access Program for research.


Share your feedback to help us improve our Novel Coronavirus Information Center. And if you experience any accessibility problems with the site or content, please contact accessibility@elsevier.com.


Introduction

Introduction

Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier

Recent events have shown us (again) how rapidly a new disease can take root and spread. Such events are accompanied by an explosion of clinical and epidemiological information and research. The goal of this website is to open whatever resources we can to help public health authorities, researchers and clinicians contain and manage this disease. We provide continually updated resources from Elsevier's content and experts. Our resources span scientific and medical journals and textbooks, educational products and a new R&D tool, and we have created an interactive global map of experts based on Scopus data. We are also participating in the Education Continuity License from the Copyright Clearance Center, allowing the use of publishers’ materials in distance learning models and other uses as required by the pandemic at no cost to the user.

Read more


Clinical information

In this section, you can find the following resources:

  • Guidelines: including new NIH and NICE guidelines; COVID-19 guidance on testing, drug therapy, ventilators, PPE, cardiovascular medicine and anesthesiology; and videos on medical procedures.
  • Elsevier Clinical Solutions: Clinical Overviews on ClinicalKey, Clinical Skills for Nursing, Interprofessional Care Plans and patient engagement resources
  • Mental and behavioral health: Guidance for anxiety and depression, including Patient Engagement videos

Elsevier COVID-19 Healthcare Hub

Gain access to our latest evidence-based practices and resources for COVID-19, covering topics from symptom management to diagnosis, treatment and ongoing wellness.

New podcast series

New podcast series

Expert Insights on COVID-19 with Elsevier

Elsevier has created a new podcast series for frontline clinicians and providers. Here, experts share their insights into the mode of transmission and pathophysiology of the virus, how medical informatics and telemedicine are used to manage the pandemic, and best practices for emergency nursing crisis preparedness.

Listen to the podcasts

Webinar: COVID-19 — global perspectives and the transformation of US healthcare

In this free webinar, hosted by the Editorial Team of Healthcare: The Journal of Delivery Science and Innovation, two experts examine how COVID-19 is changing healthcare around the world. Dr. Ashish Jha looks at lessons learned from other countries and how they inform our approach to managing this and future pandemics. Bryony Winn discusses how lessons learned from COVID will influence US healthcare delivery for years to come. Register here

Guidelines

Guidelines for clinical practice, lab testing, equipment and more

View more

Elsevier Clinical Solutions

Guidance from ClinicalKey, Clinical Solutions Nursing, Interprofessional Practice and Patient Education

Clinical Overviews on ClinicalKey are easy-to-scan clinically focused medical topic summaries designed to match the clinician workflow. Elsevier's Point-of-Care Editorial team develops them through a process that includes review and revision by a medical editor; peer reviews performed by subject matter experts; a production review to ensure consistency in style, grammar, and punctuation; and a final evaluation by the editor-in-chief.

View more

Mental and behavioral health

With the fear and uncertainty brought on by the pandemic — and calls for social distancing — many people are experiencing increased stress, anxiety and depression. Our evidence-based patient education resources support professional practice guidelines, presenting information in a way that is easy to understand and actionable. You can find more resources in Elsevier's COVID-19 Healthcare Hub.

Anxiety resources

Anxiety screening tool

Elsevier has created this anxiety screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 13 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.

Anxiety literature

Book chapters and peer-reviewed articles from Elsevier journals

View more

Depression resources

Depression screening tool

Elsevier has created this depression screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 18 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.

Clinical Skills

Clinical Overviews

Patient Education

Depression literature

Book chapters and peer-reviewed articles from Elsevier journals

Journal articles

View more

Related stories by Elsevier book authors

woman with mask in loneliness image
Video: How Fangcang Shelter Hospitals function in combating COVID-19

Video: How Fangcang Shelter Hospitals function in combating COVID-19

With Chen Wang, MD, PhD, FCCP, President of the Chinese Academy of Medical Sciences | April 1, 2020

When Wuhan faced a surge of COVID-19 patients, they couldn’t all be admitted to hospitals, and high infection risk threatened the lives of health workers. That same situation is now occurring around the world.

Read more and watch the video


Chinese-language resources

中文资源

Resources from Elsevier's Clinical Solutions team in China

Date Title Published by (CN) Published by (EN) Link
  Virology 病毒学
1月24日 新型冠状病毒国家科技资源服务系统。共享:
1)第一株病毒毒种信息及其电镜照片
2)新型冠状病毒核酸检测引物和探针序列
国家微生物科学数据中心和国家病原微生物资源库 National Microbiological Data Center;
National Pathogen Resource Collection Center
http://nmdc.cn/#/nCoV

View more resources

全球冠状病毒研究机构及研究人员分布图

基于爱思唯尔独有的全球最大的引文摘要数据库Scopus

基于爱思唯尔独有的全球最大的引文摘要数据库Scopus,聚焦冠状病毒疫情爆发及疫情控制研究。通过关键词检索分析,得到了自1996年至今已发表的22000多篇文献。在科研表现世界地图中,展示了全球表现突出的500多所科研机构(发文量超过10篇含)。其中,中国的科研机构有200多所。在这200多所中国科研机构中,中国大陆有150所,中国香港有15所,中国台湾有43所。

Read more


Research

In this section, you can find the following resources:

37,000+ articles freely available on ScienceDirect

Elsevier has made more than 37,000 coronavirus-related articles and book chapters freely available for as long as is necessary, commencing in February 2020.

The Lancet Coronavirus Hub

The Lancet's Coronavirus hub page brings together new coronavirus content from The Lancet journals as it is published.

Cell Press Coronavirus Resource Hub

On this Coronavirus Resource Hub, curated by members of the Cell Press editorial team, you'll find  content about the outbreak as it appears in Cell Press journals along with our policies for submitting papers.

1Science Coronavirus Research Repository

1science, acquired by Elsevier in 2018, was created to expand the scope of existing abstracting and analytics databases. It includes quality controlled academic and research documents in all disciplines and languages, from all countries. Its core index, 1findr, currently comprises more than 120 million metadata records, including over 30 million links to free full-text articles selected from about 100,000 referred scholarly journals. The Coronavirus Research Repository is a custom extraction from 1findr comprising articles on COVID-19, MERS, SARS and coronaviruses in general.

Centre d’information sur le nouveau coronavirus

This French version of our Novel Coronavirus Information Center includes regular updates on research in French journals.

Call for papers

Various Elsevier journals have special issues related to COVID-19

  • The Journal of Molecular Diagnostics seeks manuscripts related to SARS-CoV-2The Journal of Molecular Diagnostics — the official journal of the Association for Molecular Pathology (AMP) — is calling for manuscripts that display new or improved molecular methods which may be applied to diagnosis or monitoring of SARS-CoV-2. Accepted manuscripts will be expedited through the publication process as much as possible and will be free through Elsevier’s Novel Coronavirus Information Center and ScienceDirect. Please refer to the guide for authors for information on submission.

View more

Content hubs from other publishers

Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | American College of Cardiology| Chongqing VIP Information. Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.

You can find all these publishers and more on LitCovid — the National Library of Medicine's curated hub of scientific literature about novel coronavirus. It currently provides access to more than 3,200 articles in PubMed and is being updated daily.

Book chapters

Early-stage research: preprints on SSRN

Rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.SSRN, Elsevier’s platform for the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.

View coronavirus research on SSRN

Top 10 SSRN downloads of the week*

  1. Investigation of a superspreading event preceding the largest meat processing plant-related SARS-Coronavirus 2 outbreak in Germany 4,297
  2. Famotidine with Celecoxib Adjuvant Therapy on Hospitalized COVID-19 Patients: A Case Series 332
  3. COVID-19: Clinical Trials and Potential Therapeutic Agents — A Narrative Review 165
  4. Outbreak Prediction of COVID-19 Patients for Dense and Populated Countries Using Machine Learning 61
  5. Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 Among Healthcare Workers: Initial Experience from India 40
  6. Effectiveness of Social Measures Against COVID-19 Outbreaks in Japanese Several Regions Analyzed by System Dynamic Modeling 33
  7. β-Coronaviruses Use Lysosomal Organelles for Cellular Egress 29
  8. Further Important Characteristics of the SARS-CoV-2 IgG and IgA Antibody Response, Potentially Influencing Clinical Outcome: Immediate Antibody Degression and Dependency on Sex 29
  9. Comparative Efficacy and Safety of Pharmacological Interventions for the Treatment of COVID-19: A Systematic Review and Network Meta-Analysis of Confounder-Adjusted 36813 Hospitalized Patients 21
  10. Hospital-Acquired COVID-19 Infection – The Magnitude of the Problem 17

* Calculated on Friday, July 31

Infographic: Global research trends

Resources for drug discovery

New review of hydroxychloroquine prophylaxis clinical trials

The detailed analysis of clinical trials aims to give an overall picture of HCQ use as a COVID-19 prophylaxis around the world.

Free access to biomedical tools via Elsevier's Coronavirus Research Hub

Elsevier is offering researchers free access to a collection of clinical, biomedical and life sciences research resources and solutions for coronavirus research through October 28, 2020. These may be used by academic, government, not-for-profit and commercial researchers. We will initially give priority to researchers working on vaccine, drug and clinical research while working to increase the capacity of the platform for further use cases. The Hub includes access to ClinicalKey, Embase, SSRN, Mendeley Data, the ScienceDirect Covid-19 collection, Elsevier Text Mining (ETM), Mendeley and the Pure Covid-19 Portal. We plan to bring Reaxys and Veridata EDC online shortly. Visit Elsevier's Coronavirus Research Hub

R&D tool to capture clinical trial data is free for researchers studying COVID-19

Elsevier recently launched Veridata Electronic Data Capture (EDC), which enables clinical researchers to capture clinical trial data in a secure environment. To assist researchers working to develop vaccines and other therapies for COVID-19, Elsevier has pledged to make Veridata EDC available for free. Interested clinical researchers can contact Elsevier customer support via e-mail at covid19@elsevier.com and apply for a demo account. Following the necessary compliance training, they will receive a free 12-month license. Read the press release

Gender and COVID-19 Group on Mendeley

This collection of research, studies and other references covers the sex and gender dimensions of the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. The library is a public group, free for anyone in the world to join, access and add. References - articles, preprints, news articles, blog posts, magazine articles, reports, etc - include those compiled by Dr. Rosemary Morgan at Johns Hopkins University and colleagues from the Gender and COVID-19 Working Group, as well as those from other compilations and sources. The library on the Mendeley platform includes >500 references related to Gender and COVID-19, as well as gender and other infectious disease/epidemics, which you can locate and find resources, include direct citations and references within your work, and add additional references & folders directly to the group. We invite the community to continue posting new references as they’re published/become available even if also being added to an existing compilation elsewhere.

Hydroxychloroquine and the coronavirus: connecting the dots through the Biology Knowledge Graph

Chloroquines — inhibitors of ARDS up-regulated proteins — visualized on Elsevier's Biology Knowledge Graph

A new analysis aims to identify the effects of hydroxychloroquine and Azithromycin on proteins known to be up-regulated by severe Acute respiratory distress syndrome (ARDS) using Elsevier’s Biology Knowledge Graph. Read more on Elsevier's Pharma R&D Today blog

COVID-19 drug therapy — updated on June 29

Pharmacists in Elsevier's Clinical Solutions group write about potential treatment options for COVID-19. Read their paper.

Drug information from Elsevier's R&D Solutions

Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we use those tools to generate information relevant to combating COVID-19:

Mayo Clinic Proceedings: Possible COVID-19 Pharmacotherapies and QTc/TdP Liability

The Mayo Clinic Proceedings journal has released a pre-proof of a new paper titled Possible COVID-19 Pharmacotherapies and QTc/TdP Liability. From the abstract: "As the COVID-19 global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off label” re-purposing of drugs such as hydroxychloroquine and lopinavir/ritonavir with the potential for unwanted QT interval prolongation, and a risk of drug induced sudden cardiac death. With the possibility that a significant proportion of the world’s population could receive soon COVID-19 pharmacotherapies with torsadogenic potential for therapy or post-exposure prophylaxis, this document serves to help healthcare providers mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk to personnel of COVID 19 exposure and conserving the limited supply of personal protective equipment. Read the paper


Interactive map: global coronavirus experts

This map represents the most active institutions researching COVID-19 and related coronaviruses. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications related to COVID-19, coronaviruses and related diseases such as SARS and MERS. We then used the resulting ~28,000 publications to identify the currently active researchers and institutions that are working in these areas, the map shows the most prolific global institutions and links to their authors. (Updated: July 28, 2020)

Click on a pin to see more about the institution, the numbers of researchers and their publications that matched our query in Scopus. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.

Pure portal: Discover research collaborators and institutions globally

Use this Pure portal to discover novel coronavirus related research collaborators and institutions around the world. It uses Elsevier’s Natural Language Fingerprinting technology, scientific taxonomies and Scopus profiles and can be used to filter and find associated publications.

Additional information and examples


Public health

Here, you will find guidance and commentary from experts along with official guidance from major health organizations such as the CDC and WHO. For research on public health and related topics, see our Research section.

Dr. Fauci features Cell paper in Congressional hearing

At a recent US Congressional hearing on COVID-19, Rep. Mark Green of Tennessee, who is a physician, mentioned a study on T cell immunity by researchers at Sweden’s Karolinska’s Institute, saying “We know there are tons of people out there with immunity that we aren’t testing.” He asked Dr. Fauci to “educate America .. and all of us” on T cell immunity and its ramifications for a pandemic response.

Dr. Fauci explained:

There are two limbs of the immune response. One is an antibody, which is a protein that is made by the cells of the body to bind to the virus and is usually the hallmark of protection against infection. (The other is) the cellular immune response of T cells, and those T cells have the capability of essentially suppressing or killing cells that are infected and preventing the cells that are infected form making new viruses.

Then, holding up a copy of an article in the journal Cell, Dr. Fauci pointed out the finding that people who have not been exposed to SARS-Cov-2 but were exposed to other coronaviruses, such as those that cause the common cold, have T cells with cross-reactivity to SARS-Cov-2.

This is work we really need to pursue; we’re just at the cusp of understanding his type of response in Covid-19.

This finding could explain why some people are much more affected by COVID-19 than others – and how vaccines could function to be more effective.

The research has been featured on CNN.

Read the paper


COVID19 in America: An October Plan

Peter Hotez, MD, PhDNew in Microbes and Infection: Prof. Peter Hotez, MD, PhD, of Baylor College of Medicine describes his “October Plan” to help the United States — including its school teachers — safely return to work. Dr. Hotez is Professor of Pediatrics and Molecular Virology & Microbiology and Dean of the National School of Tropical Medicine at Baylor College of Medicine, where he is also Co-Director of the Texas Children’s Center for Vaccine Development. Read his commentary

Podcast: Richard Horton on COVID-19 vaccines

The Lancet Editor-in-Chief Richard Horton explains the current status of the Oxford and China COVID-19 vaccines, including an overview of current progress and the next steps for both. Listen here

Related papers

Webinar: COVID-19: how can we better integrate health and disaster management?

Disaster Science experts Prof. Rajib Shaw and Prof. David Alexander (both Editors-in-Chief of key disaster science journals) will outline how the Disaster Risk community could better respond to future pandemics in the wake of COVID-19.

  • Prof. Shaw will focus on specific guidelines the UN is working on for how national governments should integrate biological hazards into Disaster Risk Reduction strategies, as well as the experience of dealing with COVID-19 in Japan and East Asia.
  • Prof. Alexander will discuss key aspects of emergency planning and management for pandemics.

The webinar is Thursday, July 16 at 12 noon BST | 1 pm CET | 7 am EST | 7 pm Beijing | 8 pm Tokyo. Register here

Studies to improve face masks and disinfect the air

Special issue: Bioaerosol and infectious diseases

This special issue in the Journal of Aerosol Science, from 2018, has articles that are relevant to COVID-19.

COVID-19 Pandemic Collection in AJPM

New study on economic impact of COVID-19

A study in the Journal of Accounting and Public Policy — Estimating the COVID-19 cash crunch: Global evidence and policy — investigates how the health crisis could affect the liquidity of firms in 26 countries. In the most adverse scenario, the average firm with a limited ability to adapt production would exhaust its cash holdings in about two years.  This paper also compares different fiscal policies that governments could implement to mitigate the liquidity risk.

New test for COVID-19 may deliver faster results to more people

Scientists in Korea have developed a novel assay capable of detecting the causative viral pathogen of COVID-19 that can be run in decentralized test facilities. Read their study in The Journal of Molecular Diagnostics.

COVID-19 Data Insights Map by LexisNexis Risk Solutions

By combining their data and analytics with those of other industry stakeholders, LexisNexis Health Care created a COVID-19 dataset and interactive visualization to provide insights on at-risk populations and care capacity risks. View the map

Predictive models for the COVID-19 pandemic – a basis for decision-making

Predictive models for the COVID-19 pandemic – a basis for decision-making

Ursula von Schenck, MD, Medical Officer, Elsevier Health Analytics | March 27, 2020

We have seen the virus spread rapidly around the world. It is predicted that in an unmitigated epidemic millions of people will die from COVID-19 not accounting for the potential negative effects of health systems being overwhelmed on mortality.1, 2 Based on observations and on predictive models massive and unprecedented measures were taken worldwide.

Read more

Podcast: Richard Horton on COVID-19 vaccines

The Lancet Editor-in-Chief Richard Horton explains the current status of the Oxford and China COVID-19 vaccines, including an overview of current progress and the next steps for both. Listen here

Related papers

Progress in Disaster Science: COVID-19 Special Collection

Keeping wider disciplinary involvement in mind, the journal Progress in Disaster Science plans to publish special issues as a major learning from the evolving nature of the pandemic. Papers on the following topics related to COVID-19 response are encouraged: public health response, governance and policy analysis, emerging technologies, roles of civil societies and other stakeholders, citizen participation, collateral hazards, business continuity, recovery planning, economic/fiscal implications. Read the special collection

Journal of Aerosol Science: Special section on "Virus Aerosol Science, Sampling, and Control"

The editor, Prof. Chris Hogan, writes: "The Journal of Aerosol Science has long been a resource on understanding viruses in aerosols, methods to sample airborne viruses, and to control and inactivate airborne viruses. In this collection, we highlight numerous studies over the past decade focusing on virus aerosol science. In addition, we invite authors to contribute this virtual collection by submitting to this journal, selecting the option: "SARS-CoV-2 & Virus Aerosols." Read the special section

Why COVID-19 antibody testing is crucial — and what's needed for it to be effective

Why COVID-19 antibody testing is crucial — and what's needed for it to be effective

By David Wild, Editor, The Immunoassay Handbook | April 16, 2020

In medieval times a Friar was walking, deep in thought, along the bank of the River Thames. Suddenly he became aware of two knights arguing loudly. They drew their swords and were about to fight to the death. The Friar intervened. “Pray, gentlemen, what are you arguing about?”

Read more

JAMA coronavirus (COVID-19) update — vaccines and immunity

JAMA JN Learning | March 25, 2020

As COVID-19 spreads globally, populations who survive their illness will become immune. Mayo Vaccine Research Group Director Gregory Poland, MD, discusses antibody responses, duration of immunity, vaccine candidates and prospects for using convalescent serum to passively immunize unexposed high-risk people.

Complexities of epidemics

Complexities of epidemics

Thomas P. Erlinger, MD, MPH | VP, Clinical Analytics, Elsevier | March 18, 2020

As a former state epidemiologist, I will say that epidemics are — complex. The first complexity is that the definition of an epidemic typically references a “widespread” occurrence of a disease without a common definition of what “widespread” means. A single case of Ebola or Measles in an area that has not had any cases before would be considered an outbreak and more than a few cases in a region might be considered an epidemic, whereas in a typical season, a single case of the flu would not be considered an outbreak and a few cases in a region would not be considered an epidemic.

Read more

COVID-19 podcasts and webinars by CIDRAP

Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here

Patient resources

Video overview of Coronavirus from 3D4Medical — Watch now:

عدوى فيروس كورونا المستجد (patient education in Arabic)

عدوى فيروس كورونا المستجد

Elsevier's Patient Access Program for research

With our Patient Access Program, patients and their caregivers can receive medical or healthcare related research papers by emailing patientaccess@elsevier.com. This email is constantly monitored by our support teams, who aim to provide individual articles at no cost to patients and caregivers within 24 hours. Requesters simply need to include the article title and authors, date published, and/or the DOI or URL if available so we can locate the article as quickly as possible. Learn more

COVID-19 podcasts and webinars

Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here

More resources


Usage notice

Since January 2020, Elsevier has created an online resource center with free information in English and Mandarin on the novel coronavirus (COVID-19).

This Novel Coronavirus Information Center is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource center — including this research content — immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource center remains active.

Contributors


https://www.elsevier.com/__data/assets/file/0009/963180/elsevier-connect-logo.svg
Written by

Elsevier Connect

Written by

Elsevier Connect

This site features daily stories for the global science, health and technology communities, written by experts in the field as well as Elsevier colleagues.